$Miragen Therapeutics, Inc.(MGEN)$ ATLL is driven by HTLV-1 infection. $MGEN reported that 2 patients treated w MRG-106, both w aggressive ATLL, had stable disease (tumor blood counts & lymphadenopathy) on cobomarsen for ≥6 mos. ATLL is poorly controlled w Zidovudine, IFN alpha 2b, Lenalidomide, or chemotherapy. - Michael Goodman